Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Brochures & Literature



View Channel


Conferences | Events

Synexus focuses on Mild Cognitive Impairment studies

publication date: Nov 23, 2010
author/source: Synexus

SynexusMild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.  

Dr Bullock has over ten year's clinical trials experience in the field of dementia and is committed to this work as a vital part of the research that will ultimately benefit millions of people worldwide. Dr Christophe Berthoux, Synexus' Chief Executive, is delighted to be working with a leading expert in the field of dementia: "Dr Bullock is widely recognised for his clinical trials work in mild cognitive impairment. We are really excited about teaming up with him to start delivering more effective and faster clinical trials in this area. The financial cost of dementia across the world is set to take off. So not only do we need to address the serious health and quality of life implications of these conditions, we also need to tackle the massive financial burden as a matter of urgency." 

Berthoux continues: "Synexus is ideally placed to work in this field, with 26 Dedicated Research Centres across the globe giving us access to a wide and diverse patient population, together with highly experienced clinical investigators with in-depth local knowledge, we can get trials underway fast and deliver consistently robust results." 

Synexus has been working with Dr Bullock to ensure its medical staff are appropriately and adequately trained to deliver expertise to clinical trials in this vitally important therapy area, and is currently in talks with several major Pharma's regarding MCI studies.  

It is currently estimated that between 10% and 15% of people with MCI will go on to develop dementia. This rises to 50% after five years of diagnosis. There are estimated to be some 35 million people with Alzheimer's Disease worldwide, with around 60% of these in developing countries. Recent studies suggest that the number of people with Alzheimer's Disease in India and China is set to increase by 300% by 2025. Figures like these speak to the importance of developing effective treatments that stall the progression of dementia and ultimately prevent its occurrence. Whilst pharma continues its hunt for the holy grail of dementia, it will need to work closely with organisations like Synexus, to deliver effective studies.

For further information please visit


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners